Evaluation of recurrence after photodynamic therapy with topical methylaminolaevulinate for 157 basal cell carcinomas in 90 patients.

The aim of this study was to evaluate the effect of photodynamic therapy with topical methylaminolevulinate for the treatment of basal cell carcinomas in a single dermatological department. Ninety patients (34.4% men and 65.6% women) with a total of 157 basal cell carcinomas (111 superficial, 40 nodular, 6 unknown) were treated. Primary endpoint was clinically observed recurrence verified by biopsy 3, 6 and 12 months after treatment, then once a year. Estimated patient recurrence rates were 7% at 3 months, 19% at 6 months, 27% at 12 months and 31% at 24 months. Patients aged over 60 years had significantly higher estimated recurrence rates compared with patients aged 60 years or under (at 12 months, 35% vs. 19%, p?=?0.01). Estimated recurrence rates for tumours was 4% at 3 months, 11% at 6 months, 16% at 12 months and 19% at 24 months. There were significantly higher estimated recurrence rates for nodular basal cell carcinomas compared with superficial basal cell carcinomas (at 12 months, 28% vs. 13%, p?=?0.008). In conclusion, photodynamic therapy is only appropriate for treatment of superficial basal cell carcinoma, and, age above 60 years and histology showing nodular basal cell carcinoma are independent risk factors for developing a recurrent basal cell carcinoma.

[1]  D. Murrell,et al.  A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3‐year recurrence rates and cosmetic outcomes , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  H. Sørensen,et al.  Non-melanoma skin cancer and ten-year all-cause mortality: a population-based cohort study. , 2010, Acta dermato-venereologica.

[3]  A. Oseroff,et al.  Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies , 2009, International journal of dermatology.

[4]  Rik Roelandts,et al.  Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. , 2008, European journal of dermatology : EJD.

[5]  Menno A de Rie,et al.  Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. , 2007, Archives of dermatology.

[6]  D. Murrell,et al.  Photodynamic therapy with topical methyl aminolaevulinate for ‘difficult‐to‐treat’ basal cell carcinoma , 2005, The British journal of dermatology.

[7]  Christopher J. Arpey,et al.  Aggressive basal cell carcinoma: Presentation, pathogenesis, and management , 2004, Cancer and Metastasis Reviews.

[8]  H. Wulf,et al.  Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment , 2003, The British journal of dermatology.

[9]  M. Karagas,et al.  Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA , 1999, International journal of cancer.

[10]  Ann-Marie Wennberg,et al.  Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. , 2007, Journal of the American Academy of Dermatology.

[11]  W. Star,et al.  Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. , 2006, Acta dermato-venereologica.

[12]  P. G. Lang,et al.  Photodynamic Therapy With Topical Methyl Aminolaevulinate for ‘Difficult-to-Treat’ Basal Cell Carcinoma , 2006 .